INmune Bio Inc.
Organization details
- Legal name
- INmune Bio Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Boca Raton
- Headquarters state / province
- Florida
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- INMB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001711754
- EIN
- 47-5205835
Board of directors
-
David J. Moss · Director · Chief Executive OfficerSince 2025
-
Edgardo Baracchini Jr. · DirectorSince 2023
-
James Kelly Ganjei · DirectorSince 2023
-
James Sapirstein · DirectorSince 2026
-
Marcia Allen · DirectorSince 2023
-
Raymond Joseph Tesi · Director · President and CEOSince 2023
-
Ronnie Duane Clark · DirectorSince 2026
-
Scott Juda · DirectorSince 2023
-
Timothy J. Schroeder · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
66.5%
-
70.8%
-
74.0%
-
76.3%
-
83.8%
Board connections
1 of this board's directors also sit on 3 other boards. 2 are in the same sector.
- via James Sapirstein
-
Lunai Bioworks Inc. Same sectorvia James Sapirstein
-
Onconetix Inc. Same sectorvia James Sapirstein
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 2, 2026 | David J. Moss Director, Officer (Chief Executive Officer) | Option exercise | +9,014 | $1.40 | $12,620 |
| Jul 2, 2026 | Lowdell Mark William Officer (Chief Scientific Officer) | Option exercise | +7,211 | $1.40 | $10,095 |
| Jul 2, 2026 | Scott Juda Director | Option exercise | +14,801 | $1.40 | $20,721 |
| Sep 30, 2024 | Moss David J Officer (Chief Financial Officer), 10% owner | Open-market purchase | +10,000 | $5.29 | $52,900 |
| Sep 12, 2024 | Raymond Joseph Tesi Director, Officer (President and CEO), 10% owner | Open-market purchase | +15,380 | $6.38 | $98,124 |
| Sep 12, 2024 | Moss David J Officer (Chief Financial Officer), 10% owner | Open-market purchase | +7,690 | $6.38 | $49,062 |
| Jun 25, 2024 | Scott Juda Director | Open-market purchase | +5,000 | $7.27 | $36,350 |
| Apr 19, 2024 | Raymond Joseph Tesi Director, Officer (President and CEO), 10% owner | Grant or award | +18,028 | $8.32 | $149,993 |
| Apr 19, 2024 | Moss David J Officer (CFO, Treasurer & Secretary), 10% owner | Grant or award | +18,028 | $8.32 | $149,993 |
| Apr 19, 2024 | Lowdell Mark William Officer (Chief Scientific Officer), 10% owner | Grant or award | +14,423 | $8.32 | $119,999 |
| Apr 19, 2024 | Scott Juda Director | Grant or award | +29,603 | $8.32 | $246,297 |
| Nov 10, 2023 | Scott Juda Director | Open-market purchase | +7,000 | $6.95 | $48,650 |
| Jul 12, 2023 | Timothy J. Schroeder Director | Open-market sale | −10,000 | $11.01 | $110,100 |
| Mar 17, 2023 | Moss David J Officer (CFO, Treasurer & Secretary), 10% owner | Open-market purchase | +2,500 | $6.43 | $16,075 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about INmune Bio Inc.
Who is the CEO of INmune Bio Inc.?
Raymond Joseph Tesi is INmune Bio Inc.'s President and CEO.
How many directors are on INmune Bio Inc.'s board?
INmune Bio Inc.'s board has 9 directors: David J. Moss, Edgardo Baracchini Jr., James Kelly Ganjei, James Sapirstein, Marcia Allen, Raymond Joseph Tesi, Ronnie Duane Clark, Scott Juda and Timothy J. Schroeder.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="inmune-bio-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.